VC/PE/M&A. Healthcare Weekly(2017.11.13)

 2017-11-14 A- A+

作者:克莱尔

本期内容概览

20世纪的系统,解决21世纪的难题?A轮融了1500万美元的VisitPay想要改变美国医院支付体系。

争先恐后IPO:Apellis计划募资1.5亿美元,追逐Alexion步伐!

强手碰撞,火花四溅:医药批发商巨头麦克森斥资7.35亿美元买下CVS的药物服务单元。

承载25年的希望,Dynavax的乙肝疫苗终于遇上了FDA的绿灯。

私募融资 & IPO

1. 20世纪的系统,解决21世纪的难题?A轮融了1500万美元的VisitPay想要改变美国医院支付体系

概要:位于美国爱达荷州的医疗信息技术公司VisitPay(曾用名:iVinci)自建立之初,就立志革新美国平价医疗法案(ACA)下的医院医疗费用支付过程,使得这一支付过程对于患者来说更透明、对于医疗体系来说更自动化。公司目前A轮成功融资1500万美元,Norwest Venture Partners领投,Ascension Ventures跟投。根据公司CEO、连续创业者Ket Ivanoff,公司计划用这笔资金扩大团队规模,形成市场战略,并促进产品开发。此前在种子轮融资500万美元,投资者本身均为医疗体系集团,包括Intermountain Healthcare(一家弗吉尼亚州的Inova医疗体系)和爱达荷州首府Boise市的St.Luke’s Health System。这两家医疗体系集团通过投资及董事会上的观察席位,得以观察VisitPay能够为医疗体系带来的影响,为公司的产品在全美医疗体系的应用铺路。

相关报道:

Focusing on consumerization of healthcare billing, VisitPaycloses $15M Series A

Nov 8, 2017

VisitPay, formerly known as iVinci, is ahealth IT business founded by a serial entrepreneur with the goal of taking the stress and complexity out of healthcare billing and make the process more transparent for patients and automated for health systems. It has closed a $15million Series A round. The Boise-based business sees an opportunity to make a difference as a greater share of healthcare costs come from patients’ pockets in a post-ACA world. The 60-person company plans to use the fundingto double in size and build a marketing strategy and support product development, said Kent Ivanoff, VisitPay CEO, in a phone interview. Norwest Venture Partners led the round with participation from Ascension Ventures. The round marks the first “professional capital” VisitPay has received. The company previously raised $5 million in a Seed round with health system investors including Intermountain Healthcare,Virginia-based Inova Health System, and St. Luke’s Health System in Boise. Itis these and other integrated health systems that are the target customers forthe business, although the company also plans to include smaller players as part of its long-term strategy. “What we were struck by when we started the company in 2010 was that with ACA hospitals were facing a big change in billing but were still using 20th century technology. Our approach was to create an end to end, transparent system to address this issue and help providers and reduce confusion for consumers.” The power of having early investors in the company who were also clients is that they had seen what the company was ableto accomplish early on, Ivanoff said. Since those health systems had board observation rights, they saw the results of that first pilot platform and could see how VisitPay’s strategies would roll out in their own systems. After the successful pilot in 2014, the company took the decision to spend the following year rebuilding the platform with insights taken from the pilot to ensure it was ready for a national launch. Ivanoff claimed that bad debt rates on financeplans created by consumers in VisitPay were 75 percent lower than the bad debtrates on finance plans created in legacy systems. “We have fixed the underlying billing experience,” he said. “Patients are able to pay more and better than they otherwise would.” Ivanoff said the company made two critical hires from Cerner and IBM to oversee its marketing and commercializationstrategy. Will Reilly, who worked as vice president of product marketing for IBM, will lead client and consumer marketing. Mickey Lemon will head up sales and business development. He previously worked at EHR vendor Cerner where hewas vice president of the revenue cycle team.

Source: MedCityNews

https://medcitynews.com/2017/11/focusing-consumerization-healthcare-billing-visitpay-closes-15m-series/?rf=1

2. 争先恐后IPO:Apellis计划募资1.5亿美元,追逐Alexion步伐

概要:继近期几个临床试验成功之后,位于美国肯塔基的生物制药公司Apellis很快提出IPO计划,拟募资1.5亿美元,用于在下一轮临床药物研发中发展其领先补充药物,以及至明年第一季度之前的日常运营开销。这是Apellis继去年计划IPO募资8600万美元后,第二次提出IPO计划。Apellis的领先候选药物为APL-2,是用于治疗阵发性睡眠性血红蛋白尿症(PNH,一种罕见且严重的血液紊乱疾病)的、处于第二阶段试验中的C3抑制剂的补充药物。APL-2计划追赶Alexion的C5抑制剂Soliris(echlizumab),这是目前唯一获得FDA批准的用于治疗PNH的药物。

Apellis公司的CEO兼总裁CedricFrancois

相关报道:

Chasing Alexion, Apellis hits the start button for $150M IPO

Nov 9, 2017

Flushed with recent clinical trial wins, Apellis has moved quickly ahead with an initial public offering that it hopes will raise $150 million and give it the reserves needed to take its lead complement drug through the next phases of clinical development. This is the second time Apellis has lined upan IPO, having pulled the plug on an earlier attempt last year which aimed to raise $86 million. The Kentucky biotech, which specializes in drugs that inhibit an immune pathway known as the complement system, says the cash injection should give it operating cash until the first quarter of 2019. The firm's lead candidate, APL-2, is a complement C3 inhibitor in phase 2 trials for paroxysmal nocturnal hemoglobinuria (PNH) and is vying to take on Alexion’s Soliris (eculizumab), aC5 inhibitor which is currently the only FDA-approved drug for this rare andserious anemic blood disorder. APL-2 has also chalked up positive phase 2data in geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD) and a much bigger patient population for the drug, and is inearly-stage development for autoimmune hemolytic anemia (AIHA), which has no FDA-approved treatments. The market opportunity for APL-2 in both AMD and PNH could be sizable, but Apellis acknowledges it has competition prettymuch across the board in its target indications. Soliris is on course to reach$3 billion in sales this year, according to Alexion, and the company is already lining up a longer-acting and more potent follow-up that is in phase 3. Several other companies have PNH drugs in the clinic, including Novartis, which hasanti-C5 antibody LFG316 in mid-stage testing. There are no approved treatments for GA orAIHA, but Apellis has a number of rivals with candidates in the clinic. In GAthose include lampalizumab, a complement factor D inhibitor being developed byRoche in phase 3 testing, while drugs in development for AIHA include Rigel’s fostamatinib in phase 2.

Apellis is offering 10.7 million shares ofcommon stock at a price of $14 per share, which would raise $137 million up to$158 million if the underwriters—Citigroup, J.P. Morgan and Evercore ISI—chooseto take up an additional stock allocation.

Source: FireceBiotech

https://www.fiercebiotech.com/biotech/chasing-alexion-apellis-hits-start-button-for-150m-ipo

并购

1. 强手碰撞,火花四溅:医药批发商巨头麦克森斥资7.35亿美元买下CVS的药物服务单元

概要:麦克森公司(McKesson)近期宣布同意从CVS处买下药物服务提供商RxCrossroads,交易价格为7.35亿美元。RxCrossroads是一家位于美国肯塔基的公司,主要提供协助报销、患者服务、后勤、销售运营支持、邮件寄送药物等服务。CVS是在2015年的Omnicare交易中买下这家公司的。在交易完成后,RxCrossroads将并入麦克森公司的特殊医疗商业单元。

相关报道:

McKesson pays $735 million for CVS' pharmacy services unit

Nov 7, 2017

McKesson Corp. (NYSE: MCK) has agreed to buy pharmacy services provider RxCrossroads from CVS Health Corp. (NYSE: CVS) for$735 million. The transactions comes amid deal talks between CVS and insurerAetna Inc. (NYSE: AET). RxCrossroads, located in Louisville, Kentucky, provides reimbursement assistance, patient adherence programs, logistics, salesoperations support, as well as mail-order pharmacy services. CVS purchased the target in 2015 as part of the Omnicare deal. McKesson CEO John Hammergen says theacquisition will grow the company's hub services and patient assistance programs, "while establishing new logistics services to plasma manufacturers, which allows us to serve biopharma companies of all sizes and throughout the product life cycle.” RxCrossroads will join McKesson's specialty health business after the deal closes. McKesson distributes medical and pharmaceutical products to pharmacies and healthcare facilities. Earlier in 2017, San Francisco-based McKesson bought prescription automation company CoverMyMeds. “We have placed a priorityon deals that extend our channel influence and provide value-added services inthe specialty space," Bansi Nagji , McKesson EVP of corporate strategy and business development, said in a previous statement to Mergers &Acquisitions. In other recent healthcare deals, CryoLifeInc. (NYSE: CRY) is acquiring medical device manufactuer Jotec AG; Owens &Minor Inc. (NYSE: OMI) agreed to buy Halyard Health Inc.'s (NYSE: HYH) surgicaland infection prevention business; TPG Capital is taking surgical implantdevice maker Exactech private.

Source: Mergers & Acquisitions

https://www.themiddlemarket.com/news/cvs-sells-rxcrossroads-to-mckesson?tag=0000015a-76a3-d477-a55b-76e792870000

行业盘点

1. 承载25年的希望,Dynavax的乙肝疫苗终于遇上了FDA的绿灯

概要:在经历了两次拒绝之后的长跑后,Dynavax终于获得了FDA的认可,批准了其乙肝疫苗Heplisav-B。随着公司转型成为一家商业化的生物制药公司,Dynavax正计划和GSK逐鹿乙肝疫苗市场,与后者的主打疫苗产品Engerix-B正面对抗。在1989年GSK的Engerix-B获批后的超过25年的时间内,还没有新的乙肝疫苗获得FDA批准。FDA此次给Heplisav-B开了绿灯,使得这一药物能够为18岁及以上的所有乙肝类型患者提供治疗。

相关报道:

Persistence pays off for Dynavax as twice-rejected hepatitis Bvaccine wins FDA nod

Nov 9, 2017

Dynavax completed the long road to approval for its hepatitis B vaccine Heplisav-B on Thursday, securing an FDA nod after two previous rejections. Now, the company is set to challenge GlaxoSmithKline'sEngerix-B as it transitions into a commercial biotech. Heplisav-B's approval marks the first new hepatitis B vaccine in more than 25 years, following Engerix-B's greenlight wayback in 1989. The FDA approved the Dynavax shot for prevention of infection from all known hepatitis B subtypes in people ages 18 and older. Dynavax CEO Eddie Gray told FiercePharma his company has already hired a senior commercial team for the Heplisav-B launch,noting that the adult vaccine market is "quite a contained space"that's ideal for a small biotech's first marketing operation. He said the total commercial effort will comprise 45 to 50 people. Dynavax plans to launch the vaccine in the first quarter of 2018.

While Dynavax is willing to go it alone forthe rollout, Gray said his company is also open to hearing out prospectivepartners. Analysts with RBC Capital Markets estimate Heplisav-B will generate $300 million in peak sales. Before approval, Dynavax touted data showing its vaccine provides "higher and earlier protection with fewer doses thana currently licensed hepatitis B vaccine," according to an earlierrelease. Previously an executive at Glaxo, Gray saidmany Engerix-B recipients don't get the vaccine's required third dose.Dynavax's vaccine is given in two doses one month apart, a factor that should make it easier for recipients to complete the schedule. In combination with the efficacy data, that gives the vaccine a "very competitive profile in themarket," he said. But prospects for the hep B vaccine haven'talways been certain. The FDA turned away the shot in 2013 and 2016, requesting more safety data and more details about postmarketing plans. This time around, the agency in August delayedits review by three months to further go over the company's postmarketing plans. At the time, executives said that plan includes a phase 4 study tomonitor safety by tracking Heplisav-B recipients against those who receive theGSK shot. Going forward, Heplisav-B revenues will helpfund continued R&D activities at the company, Gray said, including inimmuno-oncology, where Dynavax has a collaboration with drug giant Merck. The biotech will also explore other applications for its newly approved adjuvant,1018. GSK's Engerix-B was among a group of hepatitis shots that generated £602 million ($810 million) last year for Glaxo. VBI Vaccines is also working on a potential challenger.

Source: FiercePharma

http://www.fiercepharma.com/vaccines/persistence-pays-off-for-dynavax-as-twice-rejected-hep-b-shot-wins-fda-nod

以上,难免有疏漏或不正确之处,请多多指出,并在文下留言处留言,谢谢!

*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。
收藏
扫描二维码,关注新浪医药(sinayiyao)公众号
360°纵览医药全局,365天放送新闻时事,医药资讯轻松一览,
精彩不容错过。
文章评论
肖恩大侠 华盖医疗基金董事总经理,北京。 毕业于北京大学工学院医学院(医学硕士)、北京大学法学院(法学硕士)。资浅PE从业人士。躬耕于太湖,游学至未名,当过医生,学过法律,改行至风险投资,喜好读书写作,经史文集,现代科技都甚喜欢,总是怀着理想,万一,实现了呢?欢迎交流医疗、文化、消费,欢迎交流一级市场、二级市场,欢迎交流国内及海外并购。 邮箱:shawn.shiqq.com
+订阅
印象笔记
有道云笔记
微信
二维码
意见反馈